Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03474718 · ClinicalTrials.gov registry record · Early Phase 1
Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia
A Early Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
NCT03474718: Clinical Trial Early Phase 1 study, sponsored by Wake Forest University Health Sciences.
NCT03474718 is a Early Phase 1 study that has not yet begun recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 16 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03474718, a Early Phase 1 study, has not yet begun recruiting, sponsored by Wake Forest University Health Sciences.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The study team will assess the efficacy of platelet-rich plasma therapy, a special blood product which is from the participant's own body, in the treatment of androgenic alopecia (also known as male pattern hair loss) in females.
Primary Outcome
Change in Severity of Alopecia Tool (SALT) from baseline. SALT scoring - This calculation is based on a scoring system. The scalp is divided into the following 4 areas: Vertex: 40% (0.4) of scalp surface area. Right profile of scalp: 18% (0.18) of scalp surface area. Left profile of scalp: 18% (0.18) of scalp surface area. Posterior aspect of scalp: 24% (0.24) of scalp surface area. Percentage of hair loss in any of these areas is the percentage hair loss multiplied by percent surface area of
Interventions
- BIOLOGICAL Platelet-rich Plasma Left Side
- BIOLOGICAL Platelet-rich Plasma Right Side
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-07 |
| Phase | Early Phase 1 |
What is known before NCT03474718 opens enrollment
NCT03474718 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 2 interventions - of which Platelet-rich Plasma Left Side is the first listed.
NCT03474718 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03474718 about?
NCT03474718 is a clinical study titled "Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia". The study team will assess the efficacy of platelet-rich plasma therapy, a special blood product which is from the participant's own body, in the treatment of androgenic alopecia (also known as male pattern hair loss) in females.
What is the current status of trial NCT03474718?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2026-07. Estimated completion is 2027-07.
What interventions are being tested in trial NCT03474718?
The interventions under investigation include: Platelet-rich Plasma Left Side (BIOLOGICAL), Platelet-rich Plasma Right Side (BIOLOGICAL).
Who is sponsoring clinical trial NCT03474718?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03474718's enrollment target sits among peer trials
16 1369th of 2000 higher than 598 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia